CXCR2 inhibition reduces viability in leukemic CD34⁺/CD38⁻ HSCs. Four AML and 1 MDS samples were treated with CXCR2 inhibitor, and viability was assessed in the CD34⁺/CD38⁻ HSC compartment. Viability in AML/MDS HSCs was significantly decreased after CXCR2 inhibition (t test, P < .05) with no change in the healthy controls (N = 3).